Lapix Therapeutics develops orally administered TIM (T-cell immunoglobulin and mucin domain) agonists to restore immune tolerance in patients with autoimmune diseases, such as Multiple Sclerosis and Rheumatoid Arthritis. By upregulating regulatory T cells and downregulating pathogenic T cells, their therapies aim to treat the underlying causes of autoimmune disorders without the side effects associated with traditional immunosuppressive treatments.
Funding
$2.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current treatments for autoimmune diseases often rely on broad immunosuppression, which can lead to significant side effects and increased risk of infection. These treatments address the symptoms of autoimmune disorders without targeting the underlying cause of immune dysregulation.
Solution
Lapix Therapeutics is developing orally administered TIM (T-cell immunoglobulin and mucin domain) agonists designed to restore immune tolerance in patients with autoimmune diseases. Their approach focuses on upregulating regulatory T cells (Tregs) and downregulating pathogenic T cells, aiming to re-establish immune balance without the need for systemic immunosuppression. By targeting the TIM pathway, Lapix seeks to address the root cause of autoimmune disorders, offering a potentially safer and more effective treatment option. Their lead candidate, LPX-TI641, is currently in Phase 1 clinical trials for Rheumatoid Arthritis, Multiple Sclerosis, and other autoimmune conditions.
Target Audience
The primary target audience includes patients suffering from autoimmune diseases such as Multiple Sclerosis, Rheumatoid Arthritis, Crohn's Disease, and Ulcerative Colitis, as well as medical professionals specializing in rheumatology, neurology, and gastroenterology.
Features
- Orally administered TIM agonists for convenient delivery
- Antigen-agnostic approach to address a broad range of autoimmune diseases
- Selective modulation of the immune system, upregulating Tregs and downregulating pathogenic T cells
- Designed to restore immune balance without causing broad immunosuppression
- LPX-TI641: A clinical-stage asset in Phase 1 trials for Rheumatoid Arthritis and Multiple Sclerosis
- LPX-TIGI: A preclinical asset designed to be gut-restricted for Ulcerative Colitis and Crohn’s disease
- Immuno-oncology program (LPX-IO) focused on antagonizing Tim3/4 receptors to restore CD8 T cell functionality in Melanoma and AML